Table 2.

Number and proportion of women who developed atypia or worse (by cytology) or cervical intraepithelial neoplasia grade 2 (CIN2) or worse (by histology) during the entire follow-up period of 13.4 years in relation to human papillomavirus (HPV) type detected at baseline among cytologically normal Danish women

HPV species and type	Proportion developing atypia or worse during follow-up				Proportion developing CIN2 or worse during follow-up
	All women with the given HPV type	Women with the given HPV type alone	Women with the given HPV type plus other high-risk HPV types except HPV16	Women with the given HPV type plus HPV16 with or without other high-risk HPV types	All women with the given HPV type	Women with the given HPV type alone	Women with the given HPV type plus other high-risk HPV types except HPV16	Women with the given HPV type plus HPV16 with or without other high-risk HPV types
	N (%)	%	%	%	N (%)	%	%	%
Alpha 9
HPV16	113 (38.2)	40.7	36.4	NA	82 (27.7)	28.5	27.2	NA
HPV31	77 (30.8)	29.4	27.6	42.6	49 (19.6)	15.7	17.1	31.9
HPV33	7 (34.8)	31.9	31.4	48.4	36 (22.0)	19.1	16.3	41.9
HPV35	17 (35.4)	27.3	40.6	20.0	11 (22.9)	18.2	28.1	0
HPV52	73 (29.7)	20.3	30.9	39.1	39 (15.9)	4.7	19.9	19.6
HPV58	24 (27.0)	16.7	29.4	22.2	18 (20.2)	16.7	22.1	11.1
Alpha 7
HPV18	38 (32.8)	23.1	37.7	28.6	24 (20.7)	15.4	23.2	19.0
HPV39	30 (21.7)	14.3	22.5	28.6	16 (11.6)	3.6	10.1	28.6
HPV45	26 (19.3)	14.9	21.3	23.1	15 (11.1)	8.5	10.7	23.1
HPV59	11 (17.5)	4.2	19.4	50.0	6 (9.5)	0	6.5	50.0
HPV68	16 (13.7)	3.8	15.6	21.4	8 (6.8)	0	7.8	14.3
Alpha 6
HPV53	21 (19.3)	0	17.1	38.1	12 (11.0)	0	7.9	28.6
HPV56	22 (18.0)	19.4	13.8	28.6	9 (7.4)	2.8	9.2	9.5
HPV66	27 (22.3)	16.7	17.2	21.8	18 (14.9)	0	12.6	25.0
Alpha 5
HPV51	27 (19.3)	17.2	16.7	29.4	18 (10.2)	8.6	6.0	23.5

*NA = not applicable.